Executive Summary
HHS obligated $92,501,232 across 1 contract during the period, representing 100% civilian spending with 0 defense-related awards. The dominant theme is BARDA-funded R&D for antimicrobials targeting resistant fungal and bacterial infections, led by a single high-materiality award to Basilea Pharmaceutica International Ltd (parent: Basilea Pharmaceutica AG). This delivers the highest-conviction bullish signal via long-term cost-sharing funding under full and open competition, with only $36,222,783 outlayed to date against a potential $267,582,260 ceiling including options. Annual revenue potential is estimated at ~$13.2M/year through 2031 or ~$24.3M/year if fully realized to 2035. Key watch item: progress on option exercises and performance milestones amid R&D execution risks.
Tracking the trend? Catch up on the prior All HHS Contracts digest from April 26, 2026.
Investment Signals(1)
- Basilea Pharmaceutica International Ltd Wins $92.5M HHS BARDA Cost-Sharing Contract for Antimicrobials R&D(MEDIUM)▲
Basilea Pharmaceutica International Ltd received a $92,501,232 total obligation (base + options up to $267,582,260) from HHS/BARDA on 2024-09-18 for biotech R&D under NAICS 541714, with a 7-year base period to 2031-09-30 and potential to 2035-12-31. Full and open competition signals market validation, though only $36,222,783 has been outlayed.
Risk Flags(1)
- Execution[MEDIUM RISK]▼
R&D execution risks on antimicrobials for resistant infections under HHS/BARDA award to Basilea Pharmaceutica International Ltd, with low outlays ($36.2M of $92.5M obligated) and unexercised options to $267.6M.
Opportunities(1)
- ◆
Potential expansion to $267.6M total via option exercises on Basilea Pharmaceutica International Ltd's HHS/BARDA cost-sharing contract for health preparedness R&D.
Sector Themes(1)
- ◆
BARDA awarded $92.5M obligation (potential $267.6M) to Basilea Pharmaceutica International Ltd under full open competition for R&D on antimicrobials (NAICS 541714, PSC AN42), emphasizing long-term health security.
Watch List(1)
- 👁
{"entity"=>"Basilea Pharmaceutica International Ltd / Basilea Pharmaceutica AG", "reason"=>"$92.5M HHS/BARDA obligation with $36.2M outlayed and potential $267.6M via options over 7-11 years", "trigger"=>"option exercises, outlay progress beyond $36.2M, performance milestones to 2031-09-30 or 2035-12-31"}
Get daily alerts with 1 investment signals, 1 risk alerts, 1 opportunities and full AI analysis of all 1 filings
More from: All HHS Contracts
🇺🇸 More from United States
View all →April 30, 2026
US Pre-Market SEC Filings Roundup — April 30, 2026
US Pre-Market SEC Filings Roundup
April 30, 2026
US Executive Compensation Proxy SEC Filings — April 30, 2026
US Executive Compensation Proxy SEC Filings
April 30, 2026
US Material Events SEC 8-K Filings — April 30, 2026
US Material Events SEC 8-K Filings
April 30, 2026
S&P 500 Energy Sector SEC Filings — April 30, 2026
S&P 500 Energy Sector SEC Filings